查詢結果分析
來源資料
相關文獻
- 使用Ticlopidine 於接受冠狀動脈繞道手術後患者之臨床結果
- 臨床路徑對冠狀動脈繞道手術病患住院天數之影響
- 冠狀動脈繞道手術臨床路徑之建立與成效評值
- 冠狀動脈繞道手術之手術部位感染危險因子之探討
- Surgical Treatment for Coronary Heart Disease Associated with Polycythemia Vera--A Case Report
- Video-Assisted Endoscopic Saphenous Vein Harvesting for Coronary Artery Bypass Grafting
- Minimally-Invasive, Direct Coronary Artery Bypass Grafting
- Postinfarction Ventricular Aneurysm: surgical Results of Aneurysmectomy and Concomitant Coronary Artery Bypass Grafting
- Coronary Artery Bypass Surgery in a 24-Year-Old Man: A Case Report and Review of Literature
- Acute Normovolemic Hemodilution in Coronary Artery Bypass Graft Surgery
頁籤選單縮合
題名 | 使用Ticlopidine 於接受冠狀動脈繞道手術後患者之臨床結果 |
---|---|
作者 | 張珩; | 書刊名 | 慈濟醫學 |
卷期 | 3:4 1991.12[民80.12] |
頁次 | 頁289-299 |
分類號 | 416.262 |
關鍵詞 | 手術; 冠狀動脈; 患者; 接受; 結果; 臨床; 繞道; |
語文 | 中文(Chinese) |
中文摘要 | 在一九九○年二月迄一九九○年十二月間,吾人對44位接受冠狀動脈繞 道手術(coronaryartery bypass graft surgery)患者進行研究。研究的主要目的在探討抗 血小板藥物--TIclopidine使用於冠狀動脈繞道手術後之效果。評估的項目包括:(1) 替代植入物(implanted graft)之暢通率(patency rate);(2)手術後殘存失血(residual ischemia)之發生率;(3)手術後心肌梗塞發生率;(4)心室功能之狀況;(5)副作用發生 情形與相關機率。為了得到更客觀的比較結果,我們將受研究患者分成二組以進 行比較分析。第一組患者有22人,每天服用TiclopidIne 300mg;第二組患者22人, 每天服用Aspirin 100mg及Dipyridamole 150mg。研究的結果發現(1)每日服用 Ticlopidine 300mg確可抑制血小板凝集反應,促進冠狀動脈及冠狀動脈繞道植入 物之暢通,減少手術後早期心肌失血與心肌梗塞的再發;(2)藉由Ticlopidine抑制血 小板生長因素(plateletgrowth factor)以減緩冠狀動脈及其替代物(graft)之粥狀硬化 過程(atherosclerosis)進而促進冠狀動脈及其繞道物之長期暢通(long-term patency) 則有待進一步研究與探討;(3)Ticiopidine 300mg於臨床上所發生的副作用極為輕 微。 由於上述之結果,我們認為使用Ticlopidine於冠狀動脈硬化疾病患者,不論是預 防心肌失血或心肌梗塞的再發,或是提升心肌灌注以強化心臟的功能均有必然的 價值。尤其是那些對Aspirin不宜的患者,Ticlopidine確可提供另一條治療的途徑。 (慈濟醫學1991:3:289-299。) |
英文摘要 | From February to December of 1990, 22 patients undergoing cardiopulmonary bypass surgery receivedTiclopidine to prevent the occurrence of occlusion of the grafted coronary vessels. In order to generally evaluatethe pharmacological effect of Ticlopidine, the patency rate of the implanted grafts was documented, the occurrence of postoperative residual ischemia and myocardial infarction were recorded, the performance of the leftventricle was assessed, and the side effect of Ticlopidine was described. Similar data related to another 22patients undergoing cardiopulmonary bypass surgery who received Aspirin and Dipyridamole were collected tocompare with the Ticlopidine group mentioned above. The results in our study revealed that (1) Ticlopidine can inhibit platelet aggregation, improve the patency ofthe graft, thus prevent the occurrence of postoperative myocardial ischemia and related infarction; (2) Becausethe time duration of this study was limited to 6 months, we do not know the effect of Ticlopidine to the longterm patency rate of the implanted grafts; (3) the side effect of Ticlopidine in clinical use was less than thosewith Aspirin and Dipyridamole. We do recommend the use of Ticlopidine to prevent the occlusion of the implanted grafts after coronaryartery bypass surgery, especially in the condition that Aspirin and Dipyridamole are contraindicated. (Tz'u-ChiMed J 1991; 3: 289-299 。 ) |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。